Email
Password

Forgot Password?


Course Overview

This intensive 12.5 hour course offers an in-depth review of the core curriculum in Clinical Lipidology for health care professionals who desire to practice at an advanced level within the field. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.

Online extras include copies of the slides, portable audio, downloadable and online references and additional self-study materials.

Course Curriculum:

  1. Lipoprotein Metabolism, Genetics, and Familial Lipid Disorders
  2. Vascular Biology and and Atherosclerosis Pathogenesis
  3. Evidence Based Medicine, Cardiovascular Risk Assessment, and Practice Guidelines
  4. Advanced Lipidology: Cardiovascular Biomarkers, Atherosclerosis Imaging, and Evidence Based Practice
  5. Obesity, Metabolic Syndrome and Diabetes Mellitus
  6. Nutrition and Non-Pharmacologic Therapy
  7. Pharmacology Part I- Lipid Lowering Drugs, Drug Interactions, and Drug Safety
  8. Pharmacology Part II- Randomized Controlled Trials, Evidence Based Treatment, and Combination Therapy

Target Audience This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

Objectives and Accreditation

ACTIVITY DATES

Release Date: March 16, 2015
Expiration Date: March 16, 2018

FEE INFORMATION

This course offered to NLA members at a cost of $750.
All other participants may purchase this course at a cost of $1250.

PROGRAM OVERVIEW

This intensive training course offers an in-depth review of the core curriculum in Clinical Lipidology for healthcare professionals who desire to practice at an advanced level within the field. The new case-based, interactive agenda will improve your clinical decision making skills and help prepare you for certification by the American Board of Clinical Lipidology (ABCL) or the Accreditation Council in Clinical Lipidology (ACCL). For those not preparing for certification, the course provides an excellent update and refresher on core concepts in Lipidology. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.

ACTIVITY TYPE

Enduring Internet Activity

TARGET AUDIENCE

This Level IV (Advanced) program is intended for physicians, registered dietitians, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and physician assistants with an interest in lipid management.

LEARNING OBJECTIVES

At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families.

At the conclusion of this activity, participants should be able to:

  • Explain lipoprotein metabolism and its role in the pathogenesis of atherosclerosis
  • Describe genetic disorders affecting lipoprotein metabolism
  • Describe the vascular biology and pathophysiology of atherosclerosis
  • Apply basic principles of evidence based medicine to enhance understanding of clinical trial results, methods for cardiovascular risk stratification, and applying new research into practice
  • Explain clinical practice guidelines, the different types of evidence used to make clinical guidelines, and the role of clinical judgment in applying guidelines to practice
  • Outline current issues and approaches to global cardiovascular risk assessment
  • Assess traditional and emerging biomarkers for the prevention and treatment of atherosclerotic cardiovascular disease
  • Review the role of subclinical atherosclerosis testing (imaging) in cardiovascular disease risk assessment and management
  • Identify the evidence base that supports current dietary recommendations for heart health
  • Describe effective diet and lifestyle (exercise, weight management) strategies for the management of dyslipidemia and cardiovascular risk
  • Identify how general dietary patterns and specific macronutrients (fats, carbohydrates) affect coronary heart disease and lipids
  • Explain how obesity and adiposopathy contribute to the metabolic syndrome and diabetes mellitus
  • Identify management strategies for the cardiometabolic risk factors of the metabolic syndrome
  • Review the mechanism of action, pharmacokinetics, and efficacy of approved drugs for the management of lipid disorders
  • Assess the side effects of lipid-altering drugs to encourage their safe use in cardiovascular disease prevention
  • Review clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention
  • Describe combination therapies for the management of complex lipid disorders and residual risk
  • Manage complex dyslipidemia and dyslipidemia in special populations

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. No partial credit awarded for ACPE credit. A statement of credit will be available for download upon completion of the online evaluation/claimed credit form. In order to receive credit, participants should complete the online course, score at least 70% on the post-test, and submit the evaluation. The deadline to claim credit is March 16, 2018.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
Estimated Time for Completion: 12.5 hours

COMMERCIAL SUPPORT

There is no commercial support provided for this activity.

CREDIT DESIGNATION

National Lipid Association

CME credit provided by the National Lipid Association


Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this Enduring Internet activity for a maximum of 12.50 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL0002.

Postgraduate Institute for Medicine

CE credit provided by the Postgraduate Institute for Medicine


Pharmacists
Accreditation Council for Pharmacy EducationPostgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number - 0809-9999-15-127-H01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 12.50 contact hour(s) (1.250 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
This educational activity for 12.5 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

For the advanced practice nurse, this activity has 3.8 contact hours of pharmacotherapy content.

FACULTY

Program Chair
Terry A. Jacobson, MD, FACP, FNLA*

Professor of Medicine
Director, Office of Health Promotion and Disease Prevention
Emory University
Atlanta, GA

Harold E. Bays, MD, FACE, FTOS, FNLA*
Medical Director/President
Louisville Metabolic and Atherosclerotic Research Center
Louisville, KY

Vera A. Bittner, MD, MSPH, FNLA*
Professor of Medicine
Section Head, Preventive Cardiology
University of Alabama at Birmingham
Birmingham, AL

Alan S. Brown, MD, FACC, FAHA, FNLA*
Director, Division of Cardiology
Advocate Lutheran General Hospital
Director, Midwest Heart Disease Prevention Center
Midwest Heart Specialists at Advocate Healthcare
Clinical Associate Professor of Medicine
Loyola University Stritch School of Medicine
Park Ridge, IL

Penny Kris-Etherton, PhD, RD, FNLA**
Distinguished Professor of Nutrition
Pennsylvania State University
University Park, PA

Kevin C. Maki, PhD, CLS, FNLA**
Chief Science Officer
Midwest Center for Metabolic & Cardiovascular Research
Chicago, IL

Carl E. Orringer, MD, FACC, FNLA*
Associate Professor of Medicine
University of Miami
School of Medicine
Miami, FL


*Denotes Diplomate, American Board of Clinical Lipidology (ABCL)
**Denotes Diplomate, Accreditation Council for Clinical Lipidology

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Faculty Financial Disclosures

Speaker
Relationship
Company

Bays, Harold
Advisory Board
Amarin Pharma; Amgen; AstraZeneca; Bristol-Myers Squibb; Catabasis; Daiichi Sankyo, Inc.; Merck & Co., Inc.; VIVUS
Consultant
Amarin Pharma; Amgen; AstraZeneca; Bristol-Myers Squibb; Catabasis; Daiichi Sankyo, Inc.; Eisai; Merck & Co., Inc.; VIVUS; WPU; Zeomedex
Research
Amarin Pharma; Amgen; Ardea Inc.; Arena Pharmaceuticals; Boehringer Ingelheim; California Raisin Board; Cargill Incorporated; Eisai; Elcelyx; Esperion; Essentialis; Forest; Gilead; Given; GlaxoSmithKline; High Point Pharmaceuticals, LLC; Hoffman LaRoche; Home Access; Merck & Co., Inc.; Micropharma Limited; Novartis; Novo Nordisk; Omthera; Pfizer; Pozen; Regeneron; Shionogi; Stratum Nutrition; Takeda; TIMI; Transtech Pharma, Inc.; Trygg Pharmaceuticals; TWI Bio; VIVUS; WPU; Xoma
Speaker
Amarin Pharma; Daiichi Sankyo, Inc.; Eisai

Bittner, Vera
Consultant
Amarin Pharma; Pfizer
Other Benefit
AstraZeneca; Roche; Sanofi-Aventis
Research
Amgen; GlaxoSmithKline; National Institutes of Health

Brown, Alan
Consultant
AstraZeneca; Merck & Co., Inc.
Speaker
Amarin; Regeneron; Merck & Co., Inc.

Jacobson, Terry
Consultant
Amarin Pharma; AstraZeneca; Merck & Co., Inc.; Regeneron/ Sanofi-aventis

Kris-Etherton, Penny
Board Membership
California Walnut Commission; McDonalds Global Advisory Council; Unilever
Contracted Research
California Strawberry Commission; California Walnut Commission; Hershey Foods & Almond Board of California; Solae/ DuPont

Maki, Kevin
Advisory Board
Abbott/ AbbVie; Amarin; Biofortis; Dairy Research Institute; Egg Nutrition Center; Matinas BioPharma; National Cattleman’s Beef Association; Omthera/ AstraZeneca; Pharmavite; Trygg Pharma
Consultant
ACH Foods; Amarin; Biofortis; Cargill; Dairy Research Institute; Egg Nutrition Center; Matinas BioPharma; National Cattleman’s Beef Association; Omthera/ AstraZeneca; Pharmavite; Trygg Pharma
Contracted Research
ACH Foods; Arctic Nutrition; Dairy Research Institute; DSM; Hillshire Brands; Ocean Spray; Omthera/ AstraZeneca; PepsiCo
Speaker
Amarin; Biofortis; Dairy Research Institute; Egg Nutrition Center; National Cattleman’s Beef Association; Ocean Spray; Omthera/ AstraZeneca

Orringer, Carl
N/A
Nothing to Disclose

Tabas, Ira
Consultant
Lipimedix; Merck & Co., Inc.

Planner Financial Disclosures

NLA
N/A
Nothing to Disclose

PIM
N/A
PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

NLA CME Reviewer

Wild, Robert
Consultant
Atherotech, Inc.


Please enter your business email address. We will email you a link that will allow you to select a new password.

Please enter your business email address to start your registration.